Table 2.

Case reports of dupilumab administration for non-esophageal eosinophilic gastrointestinal disorders

Case	Age	Sex	Allergic Comorbidities	Endoscopic findings	Eosinophil counts (/µl)	Total IgE (IU/ml)	Previous therapy	Clinical course during the dupilumab treatment	References
1	7	M	AD (Severe), FA	Esophagitis, Duodenal ulcer, Colitis	2010	1801	Food elimination, PPI, Budesonide, Prednisolone	Improvement of endoscopic and pathological findings after 6 weeks	[27]
2	14	M	BA (Severe)	Esophagitis, Esophageal stenosis, Jejunal ulcer	1890	ND	PPI, Budesonide	Improvement of endoscopic and pathological findings after 4 months	[27]
3	9	M	AD (Severe)	Esophagitis, Gastroenteritis, Colitis	ND	ND	Food elimination, PPI, Budesonide/fluticasone, Prednisolone	Improvement of abdominal symptoms and endoscopic findings Discontinuation of budesonide/fluticasone	[27]
4	15	F	BA (Severe)	Gastroenteritis, Duodenitis Colitis	ND	ND	Milk elimination, Omalizumab, Mepolizumab	Acquisition of milk tolerance	[28]
5	15	M	AD (Severe)	Duodenal ulcer	1747	2324	Food elimination, PPI, LTRA, Prednisolone	Improvement of endoscopic and pathological findings after 5 months Discontinuation of systemic steroid administration	Present case

AD atopic dermatitis, FA food allergy, BA bronchial asthma, ND no data, IgE immunoglobulin E PPI proton pump inhibitor, LTRA leukotriene receptor antagonist